Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
| CELGENE CORP /DE/CELG · Entity 15781 | See Remarks | February 17, 2018 | February 20, 2018 |
| F-star Therapeutics, Inc.SBPH · Entity 115726 | Director | June 24, 2020 | June 25, 2020 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director | September 15, 2017 | September 19, 2017 |
| Viatris IncVTRS · Entity 3277 | Director · Chief Executive Officer | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,550 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 321,550 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
CELGENE CORP /DE/
Report date February 17, 2018 · Filed February 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,419 |
Ending reported balance
After 2018-02-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-17 · Exercise / conversion · Acquired 7,283 · Balance 51,748 F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Row 2 · 2018-02-17 · Tax withholding · Disposed 2,329 · Balance 49,419 |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-17 · Exercise / conversion · Disposed 7,283 · Balance 0 F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 2,788 |
Reported balance
Holding disclosure · report date 2018-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,788 |
Filing footnotes · ownership attribution and instrument terms
F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock.
F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock.
F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
F-star Therapeutics, Inc.
Report date June 24, 2020 · Filed June 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23 | Direct | 7,500 |
Reported balance
After 2020-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-24 · Grant · Acquired 7,500 · Balance 7,500 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
TITAN PHARMACEUTICALS INC
Report date September 15, 2017 · Filed September 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2027-09-15 | Direct | 10,000 |
Reported balance
After 2017-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-15 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,329,326 |
Ending reported balance
After 2026-03-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 124,519 · Balance 1,374,576 Row 2 · 2026-03-06 · Tax withholding · Disposed 48,999 · Balance 1,325,577 F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025. Row 3 · 2026-03-06 · Exercise / conversion · Acquired 6,182 · Balance 1,331,759 F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 4 · 2026-03-06 · Tax withholding · Disposed 2,433 · Balance 1,329,326 F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 249,036 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Exercise / conversion · Disposed 124,519 · Balance 249,036 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 256,074 |
Reported balance
After 2026-03-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-06 · Grant · Acquired 256,074 · Balance 256,074 F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,362 |
Reported balance
After 2026-03-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-06 · Exercise / conversion · Disposed 6,181.4237 · Balance 12,362 F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025.
F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028.
F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs.
F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.94 · Expires 2029-11-08 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 23, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 249 | $26.04 | $6,482.72 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 3 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,611 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F4 · price: The range of prices for the shares of Common Stock is from $24.85 to $25.70. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 23, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 435 | $24.29 | $10,563.98 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,860 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F3 · price: The range of prices for the shares of Common Stock is from $23.82 to $24.79. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 22, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 430 | $26.24 | $11,281.05 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,295 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $25.83 to $26.75. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| October 01, 2021 Filed Oct 7, 2021 18:09 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 2,994 | $30.18 | $90,351.44 |
DisclosureSEC source: 0001209191-21-059977 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,725 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $30.10 to $30.41. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:43 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 13,849 | $40.89 | $566,227.44 |
DisclosureSEC source: 0001209191-21-053994 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,719 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F3 · price: The range of prices for the shares of Common Stock is from $40.54 to $41.08. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:43 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 19,395 | $39.63 | $768,699.49 |
DisclosureSEC source: 0001209191-21-053994 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,568 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $39.50 to $40.29. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:25 UTC | BioAtla, Inc. BCAB · Entity 879 | OtherCommon Stock | 34,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041213 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,963 F1 · kind: Distribution of the Issuer's shares of Common Stock by Himalaya Parent LLC, of which the reporting person is a member, for no consideration. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 20:32 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantEmployee Stock Option (right to buy) · Derivative | 154,943 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034345 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,943 Underlying: Common Stock · 154,943 shares Expires 2030-12-15 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on December 15, 2021, the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting dates. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-20-038876 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-06-23 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:17 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000395 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,476 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as the board chair and committee member of the Issuer. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:49 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051321 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,976 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as the board chair and committee member of the Issuer. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 09:01 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001209191-19-041772 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on July 10, 2019, the date of the Issuer's 2019 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 28, 2019 Filed Jun 28, 2019 15:25 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | PurchaseCommon Stock | 12,000 | $4.09 | $49,080.00 |
DisclosureSEC source: 0001209191-19-039454 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,883 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.94 to $4.10 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 09:04 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 5,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039567 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,235 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to receive shares in lieu of cash compensation for services as a director and committee member. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:05 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022347 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:50 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-18-047401 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-08-14 F1 · derivative.exercise_date: This option was granted on August 15, 2018, with the shares subject to the option vesting over a three year period from the date of grant in 36 equal monthly installments. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011406 · doc4.xml · derivative · entry 4 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,329 | $95.26 | $221,860.54 |
DisclosureSEC source: 0001209191-18-011406 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,419 Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011406 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010355 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,283 Underlying: Common Stock · 7,283 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F2 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.exercise_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.expiration_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:41 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 14,095 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001209191-18-006232 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,095 Underlying: Common Stock · 14,095 shares Expires 2028-01-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest as follows: 3,523 shares on January 29, 2019; 3,524 shares on January 29, 2020; 3,524 shares on January 29, 2021; and 3,524 shares on January 29, 2022. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 3,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066621 · doc4.xml · derivative · entry 4 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,768 | $107.06 | $189,282.08 |
DisclosureSEC source: 0001209191-17-066621 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,465 Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066621 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 3,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-058432 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,863 Underlying: Common Stock · 3,863 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 32,572 | Not disclosed Strike: $100.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-058432 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,572 Underlying: Common Stock · 32,572 shares Expires 2027-10-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 18:29 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001144204-17-048729 · v475387_4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing as of September 1, 2017. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 14,094 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001209191-17-046953 · doc4.xml · derivative · entry 5 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,094 Underlying: Common Stock · 14,094 shares Expires 2027-07-31 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 17:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046953 · doc4.xml · derivative · entry 4 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 17:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,592 | $134.10 | $347,587.20 |
DisclosureSEC source: 0001209191-17-046953 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,823 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 17:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046953 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:18 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 7,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029183 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,126 Underlying: Common Stock · 7,126 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:18 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 14,094 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001209191-17-029183 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,094 Underlying: Common Stock · 14,094 shares Expires 2027-05-01 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:25 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 12,981 | Not disclosed Strike: $113.18 | Not disclosed |
DisclosureSEC source: 0001209191-17-006371 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,981 Underlying: Common Stock · 12,981 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 16:17 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156817 · doc4.xml · derivative · entry 4 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 23, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 23, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 16:17 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 3,318 | $118.93 | $394,609.74 |
DisclosureSEC source: 0001209191-16-156817 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,557 Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 16:17 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156817 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 23, 2013 vested and settled for shares of the Company's common stock. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153645 · doc4.xml · derivative · entry 4 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,944 | $117.63 | $228,672.72 |
DisclosureSEC source: 0001209191-16-153645 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,475 Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153645 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:16 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 5,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147904 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,128 Underlying: Common Stock · 5,128 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:16 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 30,465 | $0.00 Strike: $102.18 | $0.00 |
DisclosureSEC source: 0001209191-16-147904 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,465 Underlying: Common Stock · 30,465 shares Expires 2026-10-31 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.